Market News & Trends
Hitachi Chemical to Acquire apceth Biopharma
Hitachi Chemical Advanced Therapeutics Solutions, LLC recently announced an agreement by which apceth Biopharma GmbH will join Hitachi Chemical’s PCT global services platform. apceth Biopharma…
Fortress Biotech Announces Strategic Partnership With Alexion
Fortress Biotech, Inc. recently announced that Caelum Biosciences, Inc. has signed a strategic agreement with Alexion Pharmaceuticals, Inc. to advance the development of CAEL-101 for…
Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial
Evelo Biosciences, Inc. recently announced the University of Chicago has dosed the first patient in an investigator-sponsored Phase 2a clinical trial evaluating EDP1503 in combination…
Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial
Dicerna Pharmaceuticals, Inc recently announced the dosing of the first human volunteer in its Phase 1 clinical trial of DCR-HBVS, the company’s investigational GalXCTM-based therapy…
AbbVie’s Immunology Pipeline Will Protect it From Biosimilar Erosion
Although AbbVie is feeling the impact of Humira biosimilar launch in Europe, its strong immunology pipeline is likely to protect its hold on the plaque psoriasis (PsO) and rheumatoid arthritis (RA) markets, according to GlobalData, a leading data and analytics company.
First Oral Add-On Treatment to Insulin for Treatment of Certain Patients With Type 1 Diabetes
The EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of a tablet for certain patients with type 1 diabetes mellitus.
Seelos Therapeutics Announces Successful Completion of Merger With Apricus Biosciences
Seelos Therapeutics, Inc. recently announced the completion of its previously disclosed merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics,…
Basilea Announces Collaboration With Roche to Study Derazantinib & Atezolizumab
Basilea Pharmaceutica Ltd. recently announced it entered into a collaboration with Roche to explore a combination of Basilea's derazantinib and Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab…
Proteon Therapeutics Announces Publication of Results From Phase 3 Clinical Trial
Proteon Therapeutics Inc. recently announced the publication in the Journal of Vascular Surgery of results from its Phase 3 PATENCY-1 clinical trial of investigational vonapanitase.…
Dipharma Announces FDA Acceptance of ANDA of Generic
Dipharma S.A. recently announced that the US Food and Drug Administration (FDA) accepted its nitisinone abbreviated new drug application (ANDA) for review. Nitisinone is a…
Attune Pharmaceuticals Announces $23-Million Financing
Attune Pharmaceuticals, Inc. recently announced the completion of a $23 million Series B financing. Venrock Healthcare Partners led the financing joined by new investor LifeSci…
Gerresheimer Expands to Include Irradiation of Plastic Dropper Bottles
Gerresheimer used this year's Pharmapack held in Paris, Porte de Versailles, as a platform to unveil its latest ophthalmology and rhinology services. The company has…
Hovione Issues $50-Million Bond; Embarks on New Phase of Capital Expansion
Hovione recently announced it issued a bond of $50 million dollars maturing in 2033. The bond was arranged and subscribed by Banco BPI, S.A.
Q BioMed Technology Partner Mannin Research Enters Collaboration With McMaster University
Q BioMed Inc., a biotechnology acceleration company, recently announced its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada.
Pharmapack Report Predicts Diversification of Innovation Leading to a Rise in Licensing & Partnering
Pharmapack Europe (February 6-7, Paris Expo Porte de Versailles, Paris) has released a European Drug Delivery and Packaging report, ahead of the event’s opening, which highlights, major challenges and opportunities for the industry in the year ahead.
Orion Biotechnology Reports Positive Results for Preclinical Study
Orion Biotechnology Canada Ltd. recently announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c…
Menlo Therapeutics Granted Breakthrough Therapy Designation
Menlo Therapeutics Inc. recently announced the US FDA has granted Breakthrough Therapy Designation for serlopitant for the treatment of pruritus associated with prurigo nodularis (PN).…
Auris Medical Provides Update on Intranasal Betahistine Programs
Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and CNS disorders, recently provided an…
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform
IMV Inc. recently announced that the first patient has been treated in the Phase 1 trial evaluating neoepitopes formulated in the company’s proprietary DPX delivery…
AMAG Pharmaceuticals Completes Acquisition of Perosphere
AMAG Pharmaceuticals, Inc. recently announced it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG adds…
